Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision

Bp Consulting

Status and phase: Completed; Phase 4

Conditions: Myopia

Treatments: Drug: Systane; Drug: PEG-400

Study type: Interventional

Funder types: NETWORK

Identifiers

NCT00627302

5353

Details and patient eligibility

About

To evaluate the effect of PEG-400 and Systane on quality of vision after LASIK.

Enrollment: 40 patients

Sex: All

Ages: 21+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males or females > 21 years old
• Scheduled to undergo bilateral LASIK
• Likely to complete all study visits and able to provide informed consent

Exclusion criteria

• Prior or current use of topical cyclosporine within the last 1 year
• Known contraindications to any study medication or ingredients
• Ocular disorders
• Active ocular diseases or uncontrolled systemic disease
• Active ocular allergies
• Complications at the time of surgery

Trial design

40 participants in 2 patient groups

2

Active Comparator group

Description:

Systane

Treatment:

Drug: Systane

1

Active Comparator group

Description:

PEG-400

Treatment:

Drug: PEG-400